Premium
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion
Author(s) -
Kim Kang Mo,
Kim Jong Hoon,
Park Ik Soo,
Ko GiYoung,
Yoon HyunKi,
Sung KyuBo,
Lim YoungSuk,
Lee Han Chu,
Chung Young Hwa,
Lee Yung Sang,
Suh Dong Jin
Publication year - 2009
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2008.05728.x
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , portal vein , liver function , survival rate , overall survival , transcatheter arterial chemoembolization
Background and Aim: This study aimed to evaluate the therapeutic efficacy and safety of repeated transarterial chemoembolization (TACE) with additional radiation therapy (RT) in hepatocellular carcinoma (HCC) with portal vein (PV) invasion. Methods: We performed survival analysis of consecutive HCC patients with PV invasion according to the treatment modalities after stratification by the degree of PV invasion and liver function retrospectively. Results: During 2005, 281 patients were newly diagnosed to have HCC with PV invasion at our institution. Repeated TACE or transarterial chemoinfusion (TACI) was performed in 202 (71.9%) patients and additional RT was performed for PV invasion in 43 of them. A total of 281 patients had a median survival of 5.2 months and a 2‐year survival rate (YSR) of 19.2%. Repeated TACE showed significant survival benefits compared with conservative management in patients with PV branch invasion; median survival and 2‐YSR was 10.2 vs 2.3 months and 33.7% vs 0% in Child–Pugh A categorized patients and 5.5 vs 1.3 months and 10.3 vs 0% in Child–Pugh B categorized patients, respectively ( P < 0.001). In patients with PV branch invasion, the survival rate was significantly longer with TACE/TACI plus RT than with TACE/TACI alone both in Child–Pugh A categorized patients (1‐YSR: 63.6 vs 35.6%, P = 0.031) and Child–Pugh B categorized patients (1‐YSR: 66.7 vs 7.7%, P = 0.007). Repeated TACE was well tolerated in our patients, with only one dying within one month after TACE. Conclusion: Repeated TACE with additional RT can be performed safely and showed a significant survival benefit in HCC patients with PV branch invasion with conserved liver function.